EIB finances with €15 million Amadix to develop innovative diagnostic tests for early cancer detection
Amadix is a Spanish biotech company developing non-invasive blood tests for early detection of several types of cancer before the symptoms appear.
The European Investment Bank (EIB) has signed a €15 million loan with Spanish company Amadix to support development and commercialization of innovative blood tests for early detection of several types of cancer before the appearance of symptoms. The survival rate of certain cancers such as colorectal cancer, can increase significantly if detected at an early stage.
The EIB financing will support the research, development, and manufacture of Amadix’ products from its leading test, PreveCol, for colorectal cancer diagnosis, to the development of other pipeline products: PancreaDix and DiagnoLung, for pancreatic and lung cancer detection. The loan will also support Amadix´s international expansion plan, the clinical validation of PreveCol in the United States, and stablishing a strong presence of the company in both the European and U.S. marketse.
The Valladolid-based startup is a pioneer in applying Artificial Intelligence (AI) to early cancer detection tests. Their technology is based on an algorithm that combines clinical features identified by AI with the analysis of proteins and miRNAs in plasma for early detection of premalignant lesions. The detection and removal of these lesions can effectively prevent cancer from developing.
“This loan shows the EIB’s commitment to support innovative European startups developing breakthrough medical solutions. We are delighted to join forces with research intense stratups like Amadix to expand the range of solutions for early detection of cancer, advance Europe’s plan to beat that illness and support the European medtech industry”, said EIB Director of Equity, Growth Capital and Project Finance Alessandro Izzo.
The EIB loan is guaranteed by InvestEU, the flagship EU programme to mobilise over €372 billion of additional public and private sector investment to support EU policy goals from 2021 to 2027. The project contributes to Europe’s Beating Cancer Plan and the EIB Group strategic priority of accelerating digitalisation and technological innovation.
“It is very encouraging to see organizations like the EIB supporting companies like ours contributing to the Europe’s Beating Cancer Plan and supporting our international expansion. It will enable us to bring to the European and US market our disruptive blood tests for early cancer detection. Thanks to the EIB support, more people will have access to innovative solutions such as liquid biopsy to prevent cancer, a leading cause of death worldwide, to live longer and better”, added Rocío Arroyo, Amadix’s founder and CEO.
The investments associated to the project will generate cutting edge scientific knowledge and retaining European scientific acumen. The project will also contribute to Europe’s competitiveness, boosting the innovative capacity of European based life science industries and businesses.